<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002159</url>
  </required_header>
  <id_info>
    <org_study_id>254A</org_study_id>
    <secondary_id>ITR-USA-118</secondary_id>
    <nct_id>NCT00002159</nct_id>
  </id_info>
  <brief_title>A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis</brief_title>
  <official_title>A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive
      or negative persons with blastomycosis or histoplasmosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive IV itraconazole for 2 days, then either itraconazole daily
      for 5 days or amphotericin B daily for 7 days. IV treatment is followed by consolidation with
      oral itraconazole for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>HIV Infections</condition>
  <condition>Histoplasmosis</condition>
  <condition>Blastomycosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  HIV positive or negative status.

          -  Blastomycosis or histoplasmosis.

          -  Life expectancy of at least 1 week.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Liver disease.

          -  Self-limiting fungal disease.

          -  Very severe fungal disease such as meningeal involvement.

          -  Acute respiratory disease.

        Concurrent Medication:

        Excluded at any time:

          -  Terfenadine.

          -  Astemizole.

          -  Oral midazolam.

          -  Triazolam.

          -  Cisapride.

          -  Phenytoin.

          -  Phenobarbital.

          -  Rifampin.

          -  Rifabutin.

        Excluded during oral consolidation:

          -  H2 blockers.

          -  Chronic antacids.

          -  Omeprazole.

          -  Lansoprazole.

        Patients with the following prior condition are excluded:

        Hypersensitivity to azole antifungals.

        Prior Medication:

        Excluded at any time:

        More than 3 days of amphotericin B, fluconazole, or ketoconazole.

        Excluded within 2 weeks prior to study entry:

          -  Phenytoin.

          -  Phenobarbital.

          -  Rifampin.

          -  Rifabutin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UAB Station / Infectious Division</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Arkansas for Med Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Infectious Diseases</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Inf Diseases/ Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Med Ctr / Div of Pulmonary &amp; Critical Care Med</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann Arbor Veterans Administration Med Ctr</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Missouri / Division of Infectious Diseases</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>641082792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Association / Research Med Ctr</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 1997</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Itraconazole</keyword>
  <keyword>Histoplasmosis</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Amphotericin B</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Blastomycosis</keyword>
  <keyword>Antibiotics, Antifungal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Histoplasmosis</mesh_term>
    <mesh_term>Blastomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

